Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2124427 | European Journal of Cancer | 2008 | 8 Pages |
Abstract
Three treatment cohorts were assessed, using different dosing regimens. A total of 24 women with MBC were enrolled sequentially. The regimen comprising erlotinib 100Â mg/day continuously, capecitabine 825Â mg/m2 bid on days 1 to 14 and docetaxel 75Â mg/m2 intravenously every 3 weeks on day 1 was well tolerated and was established as the MTD. Overall response rate was 67%, comprising two complete and 12 partial responders in 21 assessable patients. The most common treatment-related adverse events were gastrointestinal disorders and skin toxicities. Pharmacokinetic studies showed that exposure to the three drugs was not reduced when given in combination. These encouraging preliminary results warrant further trials of the combination in MBC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Chris Twelves, José M. Trigo, Rob Jones, Flavio De Rosa, Ashok Rakhit, Scott Fettner, Tonya Wright, José Baselga,